Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
Aged
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
BNT162 Vaccine
/ adverse effects
COVID-19
/ blood
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Humans
Immunogenicity, Vaccine
Immunoglobulin G
/ blood
Immunosuppression Therapy
Male
Middle Aged
Prospective Studies
SARS-CoV-2
/ immunology
Transplant Recipients
COVID-19
haematopoietic stem cell transplantation
neutralizing antibodies
vaccination
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
11
10
2021
received:
04
08
2021
accepted:
12
10
2021
pubmed:
30
10
2021
medline:
23
2
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
The immunogenicity and safety of Pfizer-BioNTech BNT162b2 mRNA vaccine in allogeneic haematopoietic stem cell transplantation (HSCT) recipients are unknown. We prospectively followed 152 HSCT recipients who were at least six months following transplantation and with no active acute graft-versus-host disease (GVHD). Blood samples were taken 2-4 weeks after the second vaccination and analyzed for receptor-binding domain (RBD) antibodies and neutralizing antibodies (NA). 272 immunocompetent healthcare workers served as controls. At a median of 28 days after the second vaccination, 118 patients (77·6%) developed RBD immunoglobulin G (IgG) with a geometric mean titre (GMT) of 2·61 [95% CI (confidence interval), 2·16-3·16]. In the control group 269/272 (98·9%) developed RBD IgG, with a GMT of 5·98 (95% CI 5·70-6·28), P < 0·0001. The GMT of NA in HSCT recipients and controls was 116·0 (95% CI 76·5-175·9), and 427·9 (95% CI 354·3-516·7) respectively (P < 0001). Multivariate logistic regression analysis revealed that HSCT recipients with no chronic GVHD and no immunosuppressive therapy at the time of vaccination had significantly higher levels of NA following the second vaccination. Adverse events were minimal and were less common than in healthy controls. In conclusion; the BNT162b2 mRNA vaccination is safe and effective in HSCT recipients, especially those who are immunosuppression-free. A significant fraction developed protecting NA.
Identifiants
pubmed: 34713441
doi: 10.1111/bjh.17918
pmc: PMC8652777
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
884-891Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Transpl Infect Dis. 2015 Jun;17(3):371-9
pubmed: 25817044
Blood. 2016 Jun 9;127(23):2824-32
pubmed: 27048212
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
Clin Infect Dis. 2009 May 15;48(10):1392-401
pubmed: 19368505
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Am J Transplant. 2021 May;21(5):1825-1837
pubmed: 33098200
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Heart Lung Transplant. 2021 Aug;40(8):759-762
pubmed: 34034958
Cell Host Microbe. 2020 Sep 9;28(3):486-496.e6
pubmed: 32738193
EClinicalMedicine. 2020 Dec;29:100651
pubmed: 33235985
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
EJHaem. 2021 Jun 01;2(3):520-524
pubmed: 34226903
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Vaccines (Basel). 2020 Jul 15;8(3):
pubmed: 32679691
Bone Marrow Transplant. 2017 Jul;52(7):1016-1021
pubmed: 28263288
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Infect Dis. 2019 Jun;19(6):e200-e212
pubmed: 30744963
Lancet. 2021 Apr 17;397(10283):1421-1423
pubmed: 33844964